DPEP1-Targeted Drug Discovery Services

Introduction

Dipeptidase 1 (DPEP1) is also known as renal dipeptidase. It is encoded by the DPEP1 gene located on chromosome 16 in humans. The protein encoded by this gene is a kidney membrane enzyme involved in the metabolism of glutathione and other similar proteins by dipeptide hydrolysis. The encoded protein is known to regulate leukotriene activity by catalyzing the conversion of leukotriene D4 to leukotriene E4. This protein uses zinc as a cofactor and acts as a disulfide-linked homodimer. [provided by RefSeq, Dec 2020] Some studies indicated that DPEP1 is an effective target for the treatment of respiratory disorders, such as acute respiratory distress syndrome and acute lung injury, and kidney-related diseases. Besides, the related study has verified that DPEP1 plays a central role in the pathogenesis of renal inflammation and the AKI phenotype induced by ischemia-reperfusion injury.

Direction of Drugs Discovery

• DPEP1 Inhibitor
• Developing New Clinical Effects on DPEP1 from Existing Drugs

Drugs

• DPEP1 Inhibitor- Cilastatin

What We Offer

Target Testing

CD BioSciences provides DPEP1 testing services by WB, IF, ICC, or IHC assay. The results of DPEP1 testing are used to evaluate the activities of candidates against DPEP1 or targeted diseases. You can choose one or more testing ways to detect the level of DPEP1 according to your experiment.

Hit Identification (show more)

The goal of early drug discovery is to find novel lead compounds that have the desired potency, selectivity, and ADMET properties for pre-clinical evaluation.
CD BioSciences offers hit identification services to make your finding of targeted compounds more successful and faster.
• High-Throughput Screening
• DPEP1-Targeted in Silico Virtual Screening
• Fragment-Based Screening
• High-Content Screening

Antibody Drugs Development Services (show more)

Antibody drugs exhibit many incomparable advantages, such as high specificity, affinity, and efficiency, which is an emerging direction on targeted drug development. CD BioSciences provides comprehensive services on DPEP1-targeted antibody drugs development with professional technology, extensive experience, and advanced equipment.
• Antibody Preparation Services
• Phage Display Services
• Antibody-Drug Conjugates
• Bispecific Antibody Services
• Antibody Humanization Services

Pharmacological Experiments (show more)

We will create a specific experimental plan according to your requirements, including but not limited to
• Pharmacokinetics / Pharmacodynamics
• Pharmacodynamics
• Pharmacokinetics
• Safety Pharmacology

Disease Models Screening (show more)

We will create specific disease models to accelerate your targeted drug discovery project, including but not limited to
• Diseases—Blau syndrome, spastic paraplegia, etc.
CD BioSciences will establish the specific disease models according to your requirements to evaluate the inhibitory activity of your candidates targeted DPEP1. We have various cell lines and the species of our animal models cover rats, mice, rabbits, dogs, and non-human primates.

Inquire Us

References

1. Stelzer G.; et al. The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analysis, Current Protocols in Bioinformatics (2016), 54:1.30.1 - 1.30.33.doi: 10.1002 / cpbi.5.
2. Wishart DS; et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue): D901-6.
3. Y. Zhou; et al. Therapeutic target database update 2022: facilitating drug discovery with enriched comparative data of targeted agents. Nucleic Acids Research. 50(D1): 1398-1407 (2022). PMID: 34718904.
4. Lau, A., et al., Dipeptidase-1 governs renal inflammation during ischemia reperfusion injury. Sci Adv, 2022. 8(5): p. eabm0142.
5. Choudhury, S. R., et al., Dipeptidase-1 is an adhesion receptor for neutrophil recruitment in lungs and liver. Cell, 2019. 178(5): p. 1205-1221.e1217.